The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we’ll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer
FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion
FDA Approves Ibrutinib/Rituximab for CLL/SLL
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we’ll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we’ll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer
FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion
FDA Approves Ibrutinib/Rituximab for CLL/SLL
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we’ll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer
FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion
FDA Approves Ibrutinib/Rituximab for CLL/SLL
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial CancerThe U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we’ll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer
FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion
FDA Approves Ibrutinib/Rituximab for CLL/SLL
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast CancerCoverage of stories discussed this week on ascopost.com:
FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer
FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion
FDA Approves Ibrutinib/Rituximab for CLL/SLL
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or FusionThe U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we’ll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer
FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion
FDA Approves Ibrutinib/Rituximab for CLL/SLL
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Ibrutinib/Rituximab for CLL/SLLThe U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we’ll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer
FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion
FDA Approves Ibrutinib/Rituximab for CLL/SLL
"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer